Investor Presentation First Nine Months of 2023
45
Investor presentation
First nine months of 2023
SUSTAIN trials with subcutaneous semaglutide
SUSTAIN
1
2
3
4
5
Baseline
8.1%
8.1%
8.3%
8.2%
8.4%
8.7%
-0.1
Change in
HbA1c (%)
-0.5
-0.9
-0.8
6
7
*
-1.3*
-1.2'
*
-1.1
*
*
-1.5
-1.6
-1.6*
-1.5*
*
-1.4*
-1.4*
-1.6*
-1.8
1.2
89 kg
96 kg
93 kg
92 kg
92 kg
92 kg
Baseline
-1
-1.9
-1.9
-1.4
-0.4
-0.7
8.2%
-1.8-1.5
-1.1
-1.3
95 kg
Novo NordiskⓇ
Change in
weight (kg)
-3.7
*
-4.5
-4.3
*
-5.6
-6.1 *
| semaglutide 1.0 mg
semaglutide 0.5 mg
placebo
-5.2
*
*
-3.5
-3.7*
*
-4.9
-6.4*
sitagliptin 100 mg
exenatide ER
glargine U100
-3.6
-4.6 *
-6.5*
dulaglutide 1.5 mg
-2.3
-3.0
dulaglutide 0.75 mg
* Statistically significant; SUSTAIN 1: QW sema vs placebo in drug-naïve people with T2D; SUSTAIN 2: QW sema vs sitagliptin 100 mg QD in people with T2D added to 1-2 OADS; SUSTAIN 3: QW sema vs QW exenatide ER 2.0 mg in people with T2D added
to 1-2 OADS; SUSTAIN 4: QW sema vs QD insulin glargine in people with T2D added to 1-2 OADS; SUSTAIN 5: QW sema vs placebo in people with T2D added to insulin; SUSTAIN 6: QW sema vs placebo, added to standard-of-care; SUSTAIN 7: QW sema vs
QW dulaglutide 75 mg and 150 mg in people with T2D added to 1-2 OADS: ER: Extended-release; QW: once-weekly; QD: once-daily; sema: semaglutide; T2D: type 2 diabetes, OAD: oral anti-diabeticsView entire presentation